| DrugRepV_4321 | N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (44.6 %) | NA | 24501399 |
| DrugRepV_4322 | N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (32.6 %) | NA | 24501399 |
| DrugRepV_4323 | 9H-carbazol-3-amine | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (6.1 %) | NA | 24501399 |
| DrugRepV_4324 | 7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-3.8 %) | NA | 24501399 |
| DrugRepV_4325 | N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-16 %) | NA | 24501399 |
| DrugRepV_4326 | tris[4-(dimethylamino)phenyl]methanol | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (31.8 %) | NA | 24501399 |
| DrugRepV_4327 | 6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (31.8 %) | NA | 24501399 |
| DrugRepV_4328 | 1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-1.6 %) | NA | 24501399 |
| DrugRepV_4329 | 2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-1.8 %) | NA | 24501399 |
| DrugRepV_4330 | N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (66.3 %) | NA | 24501399 |
| DrugRepV_4331 | 4-{[(5-methyl-2-thienyl)methyl]amino}phenol | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-12.6 %) | NA | 24501399 |
| DrugRepV_4332 | N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-3.4 %) | NA | 24501399 |
| DrugRepV_4333 | N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (10.2 %) | NA | 24501399 |
| DrugRepV_4334 | 2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (8.6 %) | NA | 24501399 |
| DrugRepV_4335 | N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (66.9 %) | NA | 24501399 |
| DrugRepV_4336 | N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (9.6 %) | NA | 24501399 |
| DrugRepV_4337 | 4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (34 %) | NA | 24501399 |
| DrugRepV_4338 | N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (11.6 %) | NA | 24501399 |
| DrugRepV_4339 | N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (45.7 %) | NA | 24501399 |
| DrugRepV_4340 | N-(3-chlorophenyl)-N-(4-cyanophenyl)urea | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (10.1 %) | NA | 24501399 |
| DrugRepV_4341 | N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-3.4 %) | NA | 24501399 |
| DrugRepV_4342 | N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (5.7 %) | NA | 24501399 |
| DrugRepV_4343 | 4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-24.6 %) | NA | 24501399 |
| DrugRepV_4344 | 1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (13.1 %) | NA | 24501399 |
| DrugRepV_4345 | 2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (6.4 %) | NA | 24501399 |
| DrugRepV_4346 | N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (6.2 %) | NA | 24501399 |
| DrugRepV_4347 | 2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (10.7 %) | NA | 24501399 |
| DrugRepV_4348 | N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (2.1 %) | NA | 24501399 |
| DrugRepV_4349 | 4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-0.6 %) | NA | 24501399 |
| DrugRepV_4350 | N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-2.6 %) | NA | 24501399 |
| DrugRepV_4351 | 3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-6.1 %) | NA | 24501399 |
| DrugRepV_4352 | methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (82.4 %) | NA | 24501399 |
| DrugRepV_4353 | N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (33.4 %) | NA | 24501399 |
| DrugRepV_4354 | N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (25.4 %) | NA | 24501399 |
| DrugRepV_4355 | (1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (10.5 %) | NA | 24501399 |
| DrugRepV_4356 | 4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (25.2 %) | NA | 24501399 |
| DrugRepV_4357 | N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (17.4 %) | NA | 24501399 |
| DrugRepV_4358 | 3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (26.8 %) | NA | 24501399 |
| DrugRepV_4359 | 5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-6.6 %) | NA | 24501399 |
| DrugRepV_4360 | 6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (20.9 %) | NA | 24501399 |
| DrugRepV_4361 | 2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-12.1 %) | NA | 24501399 |
| DrugRepV_4362 | N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (12.3 %) | NA | 24501399 |
| DrugRepV_4363 | 4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (1.8 %) | NA | 24501399 |
| DrugRepV_4364 | 2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (1.1 %) | NA | 24501399 |
| DrugRepV_4365 | 5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-0.3 %) | NA | 24501399 |
| DrugRepV_4366 | 2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-1.5 %) | NA | 24501399 |
| DrugRepV_4367 | 2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-15.9 %) | NA | 24501399 |
| DrugRepV_4368 | N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-11.5 %) | NA | 24501399 |
| DrugRepV_4369 | 8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (-11.7 %) | NA | 24501399 |
| DrugRepV_4370 | N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide | NA | NA | Ebola virus | GP, amino acids 196 to 205 | NA | CatL-Peptide cleavage | Decrease (8.05 %) | NA | 24501399 |
| DrugRepV_4371 | N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (24.79 %) | NA | 24501399 |
| DrugRepV_4372 | N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (31.07 %) | NA | 24501399 |
| DrugRepV_4373 | 9H-carbazol-3-amine | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (8.2 %) | NA | 24501399 |
| DrugRepV_4374 | 7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (37.87 %) | NA | 24501399 |
| DrugRepV_4375 | N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-0.67 %) | NA | 24501399 |
| DrugRepV_4376 | tris[4-(dimethylamino)phenyl]methanol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (108.4 %) | NA | 24501399 |
| DrugRepV_4377 | 6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (39.17 %) | NA | 24501399 |
| DrugRepV_4378 | 1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (5.24 %) | NA | 24501399 |
| DrugRepV_4379 | 2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-2.7 %) | NA | 24501399 |
| DrugRepV_4380 | N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (40.4 %) | NA | 24501399 |
| DrugRepV_4381 | 4-{[(5-methyl-2-thienyl)methyl]amino}phenol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-14.4 %) | NA | 24501399 |
| DrugRepV_4382 | N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-7.77 %) | NA | 24501399 |
| DrugRepV_4383 | N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (0.34 %) | NA | 24501399 |
| DrugRepV_4384 | 2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-9.26 %) | NA | 24501399 |
| DrugRepV_4385 | N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (73.49 %) | NA | 24501399 |
| DrugRepV_4386 | N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-4.08 %) | NA | 24501399 |
| DrugRepV_4387 | 4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (7.92 %) | NA | 24501399 |
| DrugRepV_4388 | N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (42.12 %) | NA | 24501399 |
| DrugRepV_4389 | N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (32.88 %) | NA | 24501399 |
| DrugRepV_4390 | N-(3-chlorophenyl)-N-(4-cyanophenyl)urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (24.49 %) | NA | 24501399 |
| DrugRepV_4391 | N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (0.86 %) | NA | 24501399 |
| DrugRepV_4392 | N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (6.5 %) | NA | 24501399 |
| DrugRepV_4393 | 4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-7.5 %) | NA | 24501399 |
| DrugRepV_4394 | 1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (35.73 %) | NA | 24501399 |
| DrugRepV_4395 | 2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-2.85 %) | NA | 24501399 |
| DrugRepV_4396 | N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (37.33 %) | NA | 24501399 |
| DrugRepV_4397 | 2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (22.44 %) | NA | 24501399 |
| DrugRepV_4398 | N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (37.22 %) | NA | 24501399 |
| DrugRepV_4399 | 4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (33.41 %) | NA | 24501399 |
| DrugRepV_4400 | N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (7.38 %) | NA | 24501399 |
| DrugRepV_4401 | 3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-0.01 %) | NA | 24501399 |
| DrugRepV_4402 | methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (90.92 %) | NA | 24501399 |
| DrugRepV_4403 | N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (12.1 %) | NA | 24501399 |
| DrugRepV_4404 | N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (21.93 %) | NA | 24501399 |
| DrugRepV_4405 | (1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-8.72 %) | NA | 24501399 |
| DrugRepV_4406 | 4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (17.7 %) | NA | 24501399 |
| DrugRepV_4407 | N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (23.22 %) | NA | 24501399 |
| DrugRepV_4408 | 3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (23.55 %) | NA | 24501399 |
| DrugRepV_4409 | 5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (3.55 %) | NA | 24501399 |
| DrugRepV_4410 | 6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (32.65 %) | NA | 24501399 |
| DrugRepV_4411 | 2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (3.23 %) | NA | 24501399 |
| DrugRepV_4412 | N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (25.12 %) | NA | 24501399 |
| DrugRepV_4413 | 4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-11.51 %) | NA | 24501399 |
| DrugRepV_4414 | 2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (5.7 %) | NA | 24501399 |
| DrugRepV_4415 | 5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-10.47 %) | NA | 24501399 |
| DrugRepV_4416 | 2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-2.95 %) | NA | 24501399 |
| DrugRepV_4417 | 2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-9.09 %) | NA | 24501399 |
| DrugRepV_4418 | N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-0.72 %) | NA | 24501399 |
| DrugRepV_4419 | 8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-10.37 %) | NA | 24501399 |
| DrugRepV_4420 | N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (3.26 %) | NA | 24501399 |
| DrugRepV_4421 | N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (91.98 %) | NA | 24501399 |
| DrugRepV_4422 | N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (98.65 %) | NA | 24501399 |
| DrugRepV_4423 | 9H-carbazol-3-amine | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (42.29 %) | NA | 24501399 |
| DrugRepV_4424 | 7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (60.65 %) | NA | 24501399 |
| DrugRepV_4425 | N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (-0.15 %) | NA | 24501399 |
| DrugRepV_4426 | tris[4-(dimethylamino)phenyl]methanol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (82.15 %) | NA | 24501399 |
| DrugRepV_4427 | 6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (88.99 %) | NA | 24501399 |
| DrugRepV_4428 | 1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (24.06 %) | NA | 24501399 |
| DrugRepV_4429 | 2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (57.39 %) | NA | 24501399 |
| DrugRepV_4430 | N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (77.83 %) | NA | 24501399 |
| DrugRepV_4431 | 4-{[(5-methyl-2-thienyl)methyl]amino}phenol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (1.34 %) | NA | 24501399 |
| DrugRepV_4432 | N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (76.53 %) | NA | 24501399 |
| DrugRepV_4433 | N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (14.51 %) | NA | 24501399 |
| DrugRepV_4434 | 2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (8.55 %) | NA | 24501399 |
| DrugRepV_4435 | N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (79.93 %) | NA | 24501399 |
| DrugRepV_4436 | N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (69.24 %) | NA | 24501399 |
| DrugRepV_4437 | 4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (65.51 %) | NA | 24501399 |
| DrugRepV_4438 | N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (80.76 %) | NA | 24501399 |
| DrugRepV_4439 | N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (65.73 %) | NA | 24501399 |
| DrugRepV_4440 | N-(3-chlorophenyl)-N-(4-cyanophenyl)urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (78.34 %) | NA | 24501399 |
| DrugRepV_4441 | N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (52.46 %) | NA | 24501399 |
| DrugRepV_4442 | N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (24.34 %) | NA | 24501399 |
| DrugRepV_4443 | 4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (39.61 %) | NA | 24501399 |
| DrugRepV_4444 | 1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (44.31 %) | NA | 24501399 |
| DrugRepV_4445 | 2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (38.88 %) | NA | 24501399 |
| DrugRepV_4446 | N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (38.54 %) | NA | 24501399 |
| DrugRepV_4447 | 2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (50.22 %) | NA | 24501399 |
| DrugRepV_4448 | N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (51.28 %) | NA | 24501399 |
| DrugRepV_4449 | 4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (39.55 %) | NA | 24501399 |
| DrugRepV_4450 | N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (33.84 %) | NA | 24501399 |
| DrugRepV_4451 | 3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (23.55 %) | NA | 24501399 |
| DrugRepV_4452 | methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (77.79 %) | NA | 24501399 |
| DrugRepV_4453 | N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (56.45 %) | NA | 24501399 |
| DrugRepV_4454 | N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (47.55 %) | NA | 24501399 |
| DrugRepV_4455 | (1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (-3.09 %) | NA | 24501399 |
| DrugRepV_4456 | 4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (72.37 %) | NA | 24501399 |
| DrugRepV_4457 | N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (47.94 %) | NA | 24501399 |
| DrugRepV_4458 | 3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (53.23 %) | NA | 24501399 |
| DrugRepV_4459 | 5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (28.07 %) | NA | 24501399 |
| DrugRepV_4460 | 6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (25.6 %) | NA | 24501399 |
| DrugRepV_4461 | 2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (37.16 %) | NA | 24501399 |
| DrugRepV_4462 | N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (61.47 %) | NA | 24501399 |
| DrugRepV_4463 | 4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (66.62 %) | NA | 24501399 |
| DrugRepV_4464 | 2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (32.44 %) | NA | 24501399 |
| DrugRepV_4465 | 5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (30.53 %) | NA | 24501399 |
| DrugRepV_4466 | 2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (47.39 %) | NA | 24501399 |
| DrugRepV_4467 | 2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (49.81 %) | NA | 24501399 |
| DrugRepV_4468 | N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (51.17 %) | NA | 24501399 |
| DrugRepV_4469 | 8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (41.66 %) | NA | 24501399 |
| DrugRepV_4470 | N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (40.85 %) | NA | 24501399 |